Failure of intravenous silibinin monotherapy to prevent hepatitis C genotype 2A liver graft reinfection

Hepatitis Monthly

Volumn 12, Issue 6, 2012, Pages 81-84

  Aghemo, Alessio ^a   Bhoori, Sherrie ^b   De Nicola, Stella ^a   Mazzaferro, Vincenzo ^b   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Hepacivirus; Liver transplantation; Silybin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON; RIBAVIRIN; SILIBININ; SILYMARIN; VIRUS RNA;

AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENOTYPE; GRAFT INFECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER GRAFT; REINFECTION; RELAPSE; VIRUS LOAD;

EID: 84864470580     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.xxx     Document Type: Article

References (17)

1. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virusrelated graft cirrhosis after liver transplantation. Hepatology. 2000;32(4 Pt 1):852-8.
2. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999;29(1):250-6.
3. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8(3):679-87.
4. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail. Hepatology. 2011;54(1):3-5.
5. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54(1):20-7.
6. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-44.
7. Beinhardt S, Rasoul-Rockenschaub S, Scherzer TM, Ferenci P. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J Hepatol. 2011;54(3):591-2; author reply 2-3.
8. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol. 2010;52(6):951-2.
9. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008;135(5):1561-7.
10. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008;47(2):605-12.
11. Freedman N, Curto T, Morishima C, Seeff L, Goodman Z, Wright E, et al. Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Aliment Pharmacol Therapeutics. 2011;33(1):127-37.
12. Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, et al. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology. 2010;138(2):671-81, 81 e1-2.
13. Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS. Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol. 2012;56(5):1019-24.
14. Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology. 2010;138(3):1112-22.
15. Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pecheur EI, et al. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One. 2011;6(1):e16464.
16. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol. 2012;56 (Suppl 1):S88-100.
17. May MM, Lorengel H, Kreuter J, Zimmermann H, Ruebsamen-Schaeff H, Urban A. RNA-dependent RNA polymerases from different hepatitis C virus genotypes reveal distinct biochemical properties and drug susceptibilities. Biochim Biophys Acta. 2011;1814(10):1325-32.